Comparative Pharmacology
Head-to-head clinical analysis: STALEVO 100 versus STALEVO 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STALEVO 100 versus STALEVO 50.
STALEVO 100 vs STALEVO 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stalevo 100 is a combination of carbidopa, levodopa, and entacapone. Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine by aromatic L-amino acid decarboxylase (AAAD), thereby increasing dopamine levels in the brain. Carbidopa inhibits peripheral AAAD, reducing the conversion of levodopa to dopamine outside the brain, which increases the amount of levodopa available for CNS entry and decreases side effects. Entacapone is a reversible inhibitor of catechol-O-methyltransferase (COMT), which reduces the metabolism of levodopa to 3-O-methyldopa, prolonging the half-life and duration of action of levodopa.
Stalevo 50 is a combination of carbidopa, levodopa, and entacapone. Levodopa is converted to dopamine in the brain, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its central availability. Entacapone is a selective, reversible inhibitor of catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa to 3-O-methyldopa, thereby prolonging its half-life.
One tablet (carbidopa 25 mg / levodopa 100 mg / entacapone 200 mg) orally three to four times daily, maximum 8 tablets per day.
One tablet (carbidopa 12.5 mg, levodopa 50 mg, entacapone 200 mg) orally, up to 8 tablets per day in divided doses, adjusting based on individual response. Maximum levodopa dose: 800 mg/day.
None Documented
None Documented
Levodopa: 1.5-2 h (peripherally); with carbidopa: prolongs to ~2.5 h. Carbidopa: 2-3 h. Clinical context: requires continuous dopaminergic stimulation to avoid motor fluctuations.
Levodopa: 1-3 hours (short half-life necessitates frequent dosing; COMT inhibition by entacapone prolongs elimination half-life by ~1-2 hours vs levodopa alone). Carbidopa: 1-2 hours. Entacapone: 0.4-0.7 hours (terminal half-life in plasma).
Renal: ~90% (levodopa metabolites), ~80% (carbidopa unchanged and metabolites); biliary/fecal: minimal
Renal: ~80% (carbidopa: 70% unchanged, levodopa metabolites: 70-80% as HVA/DOPAC); Fecal: ~20% (entacapone: primarily as glucuronide conjugates via bile).
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent